Abstract: Methods of production and apparatuses for production for stably producing healthy and functional platelets, and methods for determining operating conditions of an apparatus for producing platelets are provided. The present invention relates to methods of production comprising a step of culturing megakaryocytes in a platelet production medium C, wherein the step of culturing comprises a step of stirring a medium C in containers 1, 4 using stirring mechanisms 2, 5. In one method of production, the step of stirring comprises reciprocating stirring blades 21, 24 in the stirring mechanisms 2, 24 such that any of predetermined turbulent energy, shearing stresses, or Kolmogorov scale is produced, in the medium C. In another method of production, the step of stirring comprises pivoting a stirring blade 51 in the stirring mechanism 5 wherein a plurality of stationary members 53 is placed therearound in a bottom region 4e of the container 4 such that the step of stirring produces turbulence in the medium C.

Abstract: A cell culturing method comprising culturing hematopoietic stem cells or hematopoietic progenitor cells, or both the hematopoietic stem cells and the hematopoietic progenitor cells with their undifferentiated state maintained using a device for cell culture. The device includes a base material having a culture section with a plurality of pores, wherein the culture section has a Young's modulus of at least 3 GPa measured according to JIS K 7161-1.

Abstract: The present invention relates to a method for improving proliferative property of a CMP or a myeloid progenitor cell, including a step of forcibly expressing a MYC family gene and BMI1 gene in any cell in the process of differentiation from a hematopoietic progenitor cell into a myeloid progenitor cell, wherein the myeloid progenitor cell is a progenitor cell of macrophage, dendritic cell, granulocyte, erythroblast, or erythrocyte.

Abstract: The present invention is to provide an antisense oligomer or a pharmaceutically acceptable salt thereof capable of treating Werner syndrome without direct repair of a mutated gene. The present invention provides an antisense oligomer or a pharmaceutically acceptable salt thereof which consists of a base sequence complementary to the base sequence of the following (i) or (ii): (i) a contiguous base sequence of 15 or more bases in the base sequence shown in SEQ ID NO: 1; or (ii) a contiguous base sequence of 15 or more bases in the base sequence shown in SEQ ID NO: 1, having deletion, substitution, or insertion of one or more bases; and which is capable of causing skipping of the 27th exon in a human WRN gene.

Abstract: Healthy functional platelets are mass produced. A method for producing platelets, comprising: (1) a culture step of culturing megakaryocytes in a platelet producing medium in the presence of mechanical stress and platelet production promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a harvest step of harvesting the platelets obtained by the culture step; wherein the culture step comprises: (a) a step of promoting a release of the platelet production promoting factors from megakaryocytes by mechanical stress; and/or (b) a step of externally adding platelet production promoting factors including MIF, NRDc, and IGFBP2.

Abstract: The present invention provides a method for producing megakaryocytes that have an increased capacity to produce platelets, the method comprising a step of culturing, under conditions that cause the death of cells that do not express a gene that is specifically expressed by megakaryocytes, cells that have the capacity to differentiate into megakaryocytes.

Abstract: The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.

Abstract: Healthy functional platelets are mass produced. A method for producing platelets, comprising: (1) a culture step of culturing megakaryocytes in a platelet producing medium in the presence of mechanical stress and platelet production promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a harvest step of harvesting the platelets obtained by the culture step; wherein the culture step comprises: (a) a step of promoting a release of the platelet production promoting factors from megakaryocytes by mechanical stress; and/or (b) a step of externally adding platelet production promoting factors including MIF, NRDc, and IGFBP2.

Abstract: Provided is a method for producing a stem cell clone, which comprises the steps of: (i) introducing into stem cells an exogenous gene associated with induction of differentiation into somatic cells; (ii) inducing differentiation of the stem cells, introduced with an exogenous gene, into the somatic cells; (iii) dedifferentiating the differentiation-induced somatic cells; and (iv) isolating stem cells having the exogenous gene incorporated into a chromosome thereof from a colony of the stem cells formed in step (iii).

Abstract: A method for producing a target cell includes producing a target cell by culturing a raw material cell in a serum-free medium containing: at least one culture factor selected from a growth factor and a differentiation inducing factor; human serum albumin; and at least one additive selected from a group consisting of a Src inhibitor, a PKC activator, methylcellulose, an Essential 8 medium, recombinant human serum albumin, and non-human animal serum albumin.

Abstract: The present invention provides a method for producing a platelet comprising: (a) a step of culturing a megakaryocyte for at least 6 days in a platelet production medium in which a turbulent flow is generated; and (b) a step of injecting the medium comprising the megakaryocyte that has undergone step (a) into a predetermined platelet production device to expose the megakaryocyte to a laminar flow.

Abstract: A production method for a genetically modified megakaryocyte, the method including a step of introducing a CRISPR-associated (Cas) family protein and guide RNA (gRNA) into a megakaryocyte to modify a subject gene, in which the Cas family protein and the gRNA to be introduced into the megakaryocyte in the step form a complex beforehand. This production method is useful as a technique for producing a genetically modified megakaryocyte and a modified platelet.

Abstract: The problem that differences among lots in components and amounts of growth factors and the like in platelet-rich plasmas derived from an autologous plasma and the freeze-dried preparations thereof are large, and the effects of the lots are not kept constant is solved. Specifically, a freeze-dried preparation comprising megakaryocytes and platelets induced to differentiate from stem cells, a pharmaceutical composition comprising the freeze-dried preparation, and the like are provided.

Abstract: An image forming system includes a recording processing portion, an acquirement processing portion, and an output processing portion. The recording processing portion records a consumed amount of a consumable consumed by an image forming apparatus per predetermined unit time. The acquirement processing portion acquires prediction data that indicates a predicted consumed amount of the consumable per the unit time for a time period from a predetermined standard time, based on a comparison result between: a first record result corresponding to a first time period extending to a reference time; and a second record result corresponding to a predetermined second time period extending to the standard time, among a record result recorded by the recording processing portion, the reference time being a predetermined specific time period earlier than the standard time. The output processing portion outputs the prediction data acquired by the acquirement processing portion.

Abstract: An object of the present invention is to provide a method of efficiently producing a maturated megakaryocytic cell line from hematopoietic progenitor cells. The present invention provides a method for producing megakaryocytes from hematopoietic progenitor cells, comprising (i) forcibly expressing an apoptosis suppression gene and an oncogene in hematopoietic progenitor cells and culturing the cells, and (ii) arresting forced expression of the apoptosis suppression gene and the oncogene and culturing the hematopoietic progenitor cells.

Abstract: The present invention provides a method for producing a pluripotent stem cell released from resistance to differentiation into mesendodermal lineage, including subjecting a pluripotent stem cell to a treatment for activating an integrin ?1-?-catenin signal transduction pathway (excluding contacting the pluripotent stem cell with laminin 421 or a fragment thereof and/or laminin 121 or a fragment thereof), and the like.

Abstract: Provided is a device for cell culture, the device including: a base material including a culture section used for culturing hematopoietic stem cells or hematopoietic progenitor cells, or both the hematopoietic stem cells and the hematopoietic progenitor cells, wherein the culture section includes a plurality of pores, and wherein a Young's modulus of the culture section measured according to JIS K 7161-1 and JIS K 7161-2 is at least 3 GPa.

Abstract: An image forming system includes a recording processing portion, an acquirement processing portion, and an output processing portion. The recording processing portion records a consumed amount of a consumable consumed by an image forming apparatus per predetermined unit time. The acquirement processing portion acquires prediction data that indicates a predicted consumed amount of the consumable per the unit time for a time period from a predetermined standard time, based on a comparison result between: a first record result corresponding to a first time period extending to a reference time; and a second record result corresponding to a predetermined second time period extending to the standard time, among a record result recorded by the recording processing portion, the reference time being a predetermined specific time period earlier than the standard time. The output processing portion outputs the prediction data acquired by the acquirement processing portion.

Abstract: Provided is a method for inducing mesoderm, comprising a step of bringing pluripotent stem cells into contact with bone morphogenetic protein 4 (BMP4) or CHIR for at least 3 days.

Abstract: The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.